.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after an average consequence of 11 months, clients with metastatic gastrointestinal tumors who acquired biomarker-matched therapies based upon circulating cyst DNA profiling showed a greater professional advantage than those getting unequaled treatment.